Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 5/20 | 0.60 |
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2803425 | 1.00 | DNM1 (0.60) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL1679147 | 1.00 | — | — | |
| SCHEMBL2802283 | 1.00 | DNM1 (0.60) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL10588206 | 1.00 | DNM1 (0.60) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL2802098 | 1.00 | DNM1 (0.60) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL908741 | 0.97 | — | — | |
| SCHEMBL514226 | 0.88 | — | — | |
| SCHEMBL15899616 | 0.79 | DNM1 (0.55) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL11071352 | 0.79 | DNM1 (0.55) | DNM1TSHRTHRBCA12CA1 | |
| SCHEMBL1405732 | 0.79 | DNM1 (0.55) | DNM1TSHRTHRBCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785574-B2 | Bridged metallocene compound, olefin polymerization catalyst containing the same, and ethylene polymer obtained with the catalyst | MITSUI CHEMICALS, INC. (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20140114031-A1 | BRIDGED METALLOCENE COMPOUND, OLEFIN POLYMERIZATION CATALYST CONTAINING THE SAME, AND ETHYLENE POLYMER OBTAINED WITH THE CATALYST | PRIME POLYMER CO., LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| EP-2218725-B1 | BRIDGED METALLOCENE OLEFIN POLYMERIZATION CATALYST AND ETHYLENE POLYMER OBTAINED BY USING THE CATALYST | MITSUI CHEMICALS INC (JP) | 2013-10-23 | — | — | EP | disclosed |
| US-20100292421-A1 | BRIDGED METALLOCENE COMPOUND, OLEFIN POLYMERIZATION CATALYST CONTAINING THE SAME, AND ETHYLENE POLYMER OBTAINED WITH THE CATALYST | MITSUI CHEMICALS, INC. | 2010-11-18 | — | — | US | disclosed |
| EP-2218725-A1 | BRIDGED METALLOCENE COMPOUND, OLEFIN POLYMERIZATION CATALYST USING THE COMPOUND AND ETHYLENE POLYMER OBTAINED BY USING THE CATALYST | Mitsui Chemicals, Inc. (JP) | 2010-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292421-A1 | BRIDGED METALLOCENE COMPOUND, OLEFIN POLYMERIZATION CATALYST CONTAINING THE SAME, AND ETHYLENE POLYMER OBTAINED WITH THE CATALYST | CAD, ENDOD1, CCT7 | DNM1 465/4885TSHR 4068/4885THRB 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.